argenx SE

ARGX remains in a Stage 2 advance with its long-term uptrend intact, but the recent 9/20 EMA cross to the downside and weakening momentum suggest a short-term consolidation. Medium-term structure stays bullish above the 50-day SMA, yet execution timing is unfavorable now. Stalk for a clearer stabilization or a resolution back above EMAs before committing new capital.

• ↑Q2’26 VivGuard net sales $1.5B, +60% YoY adoption in MG/CIDP
• ↑PDUFA May 10, 2026 for seronegative MG could expand addressable market by ~11K patients
• ↓Q2’26 operating expenses hit $1B, pressuring profit margins